CADTH pCODR Expert Review Committee
Terms of Reference

FEBRUARY 2018
# Record of Updates

<table>
<thead>
<tr>
<th>Update</th>
<th>Version</th>
<th>Reported on CADTH website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>April 2011</td>
<td>April 19, 2011</td>
</tr>
<tr>
<td>1</td>
<td>February 2013</td>
<td>July 2013</td>
</tr>
<tr>
<td>2</td>
<td>May 2014</td>
<td>July 2014</td>
</tr>
<tr>
<td>3</td>
<td>May 2016</td>
<td>September 2016</td>
</tr>
<tr>
<td>4</td>
<td>February 2018</td>
<td>March 2018</td>
</tr>
</tbody>
</table>
Table of Contents

Record of Updates.................................................................................................................1
1 pCODR Expert Review Committee Purpose........................................................................3
2 Mandate .................................................................................................................................3
3 Responsibilities ......................................................................................................................3
4 Accountability & Reporting ....................................................................................................4
5 Membership .........................................................................................................................4
  5.1 Composition ......................................................................................................................4
  5.2 Requirements ....................................................................................................................4
  5.3 Officers ............................................................................................................................ 5
  5.4 Nomination/Appointment Process ....................................................................................5
  5.5 Term of Appointment .......................................................................................................5
  5.6 Withdrawal from Committee ..........................................................................................5
  5.7 Voting Rights ...................................................................................................................6
6 Committee Support ..............................................................................................................6
7 Meetings ...............................................................................................................................6
  7.1 Frequency of Meetings ....................................................................................................6
  7.2 Notice of Meetings ...........................................................................................................6
  7.3 Quorum ...........................................................................................................................6
  7.4 Attendance .......................................................................................................................6
  7.5 Attendees ........................................................................................................................6
  7.6 Agenda ............................................................................................................................7
  7.7 Conflict of Interest Disclosure .........................................................................................7
  7.8 Decisions ........................................................................................................................7
  7.9 Record of Meetings .........................................................................................................8
8 Reimbursement of Expenses ...............................................................................................9
9 General Provisions ..............................................................................................................9
  9.1 Code of Conduct .............................................................................................................9
  9.2 Conflict of Interest Guidelines .........................................................................................9
  9.3 Indemnification ...............................................................................................................9
10 Confidentiality .....................................................................................................................9
11 Terms of Reference ............................................................................................................9
Appendix A: pCODR Guiding Principles ..............................................................................10
Appendix B: pERC Deliberative Framework ..........................................................................11
Appendix C: Responsibilities of pERC Chair & pERC Vice-Chair .........................................14
1 pCODR Expert Review Committee Purpose

The purpose of the pCODR expert review committee (pERC) is to make cancer drug funding recommendations to participating provincial/territorial Ministries of Health, provincial cancer agencies and federal drug programs that can be used by these jurisdictions to guide their cancer drug funding decisions. The pERC recommendations must consider the evidence-based reviews of the clinical effectiveness and cost effectiveness of cancer drug products conducted by pCODR and the input provided by patient advocacy groups and jurisdictions.

As of April 1, 2014, pCODR is a program of the Canadian Agency for Drugs and Technologies in Health (CADTH). The pCODR Guiding Principles (Appendix A) and the pERC Deliberative Framework (Appendix B) should be used to guide and frame the work of pERC.

2 Mandate

The mandate of the pERC is to provide cancer drug funding recommendations, including conditions and/or criteria for coverage where appropriate, to the participating provincial/territorial Ministries of Health, provincial cancer agencies and federal drug programs, based on Submissions or Resubmissions.

Upon request, the pERC also provides advice to jurisdictions on cancer drug products, which may or may not result in a change to a previously issued pERC recommendation. A Request for Advice may be made by the CADTH pCODR Advisory Committee (PAC) or the Provincial Advisory Group (PAG).

3 Responsibilities

The responsibilities of the pERC include:

a) to establish, maintain, and apply standards and methodologies to evaluate the therapeutic value and cost effectiveness of cancer drug products for active disease management;

b) to consider Submissions and Resubmissions made by manufacturers, provincially-recognized clinician-based tumour groups and/or the PAG, and all related clinical reviews and economic reviews prepared and provided in accordance with the pCODR’s standards;

c) to evaluate Submissions, Resubmissions and Requests for Advice in terms of therapeutic advantages and disadvantages, cost-effectiveness, patient perspective and PAG perspective on the impact of the cancer drug product under review, compared to accepted or existing therapies;

d) to recommend, after consideration of a Submission or a Resubmission, to the provincial/territorial Ministries of Health and provincial cancer agencies, those new cancer drug products for active disease management, which may be considered for funding and advise the Provincial/Territorial Ministries of Health, provincial cancer agencies and federal drug programs, of the conditions and/or criteria under which such products may be funded;

e) to provide reasons for every recommendation made to the provincial/territorial Ministries of Health and provincial cancer agencies, for public dissemination.

f) to provide advice and, if appropriate, a change to a previously issued recommendation, in response to every Request for Advice made by the PAC or PAG;

g) to consider feedback provided by Submitters, Manufacturers (if not the submitter), the PAG and patient advocacy groups, on an Initial Recommendation before issuing a Final Recommendation, unless there are instances where
the pERC determines an Initial Recommendation meets the criteria for early conversion to a Final Recommendation;

h) to deliberate on a Submission or Resubmission again, and, if appropriate, to change a Final Recommendation, in response to a Procedural Review submitted to pCODR and decided upon by the President and CEO of CADTH, on the advice of the pCODR Advisory Committee (PAC) Chair and Vice-Chair, who will determine if the grounds for a procedural review exist.

4 Accountability & Reporting

The pERC is an expert advisory committee that provides advice to the provincial/territorial Ministries of Health, provincial cancer agencies and federal drug programs. The pERC is accountable to the President and CEO of CADTH through the pERC chair. The pERC Chair shall report back to the President and CEO of CADTH at a minimum on a biannual basis in consultation with the pCODR Director.

5 Membership

5.1 Composition

The committee is composed of 13-18 members, including the Chair as follows:

- Five to seven cancer specialists (oncologists)
- One “non-oncology” physician
- Three health economists
- One to two pharmacists
- Two hematologists
- Two patient representatives and a patient representative alternate

At least one of these members should also have expertise in health ethics.

If vacancies exist due to lack of available expertise, the overall composition of the pERC will be discussed with the President and CEO of CADTH to determine appropriate action, which may include but is not limited, to a temporary or permanent revision in the composition of pERC.

5.2 Requirements

All pERC members must meet all of the following requirements:

- currently not employed by any pharmaceutical manufacturer or related companies;
- able and willing to comply with Conflict of Interest and Confidentiality requirements of the pCODR;
- availability/commitment of time to participate fully in the pERC;
- knowledge of, experience with, and understanding of, issues related to cancer and its management (diagnosis, treatment and care);
- knowledge and understanding of pCODR’s mandate and the mandate of the committee, including their role in the broader cancer system as well as the healthcare system;
- willingness to work within the defined processes and parameters for reviewing cancer agents, including evidence-based medicine, cost-effectiveness and patient values;
- experience in committee and/or community work;
- ability to communicate effectively;
• ability to acquire the information and adopt the skills needed to successfully negotiate important issues;
• strong listening skills;
• ability to act with integrity and independence of specific interests;
• ability to relate to and respect a diverse range of values and beliefs;
• ability to gain respect and credibility within a diverse range of stakeholders and the wider public;
• ability to work constructively as a member of a team

pERC members representing a healthcare specialty must also meet the following requirements:
• a professional degree from a recognized institution in at least one of the following disciplines: medicine, pharmacy, pharmacology or health economics;
• be in active practice and/or research in either the community, hospital and/or academic setting;
• should have an understanding of the use and delivery of oncology drugs within the Canadian context.

pERC patient members must also meet the following requirements:
• Personal knowledge of, experience with, and understanding of issues related to cancer and its management (diagnosis, treatment and care);
• Demonstrated understanding and appreciation of patient needs and priorities;
• An overall understanding of other patient issues and health care concerns that may impact cancer patient communities on a broader scale.

More details on requirements for pERC members are set out in the pCODR Nomination/Application Information Package, which is available on the CADTH website.

5.3 Officers
The pERC shall have a Chair and a Vice-Chair. The responsibilities of the pERC Chair and the pERC Vice-Chair are laid out in Appendix C.

5.4 Nomination/Appointment Process
The nomination and appointment process shall be as set out in the Nomination/Application Information Package, which is available on the CADTH website.

5.5 Term of Appointment
Of the first patient members appointed to the pERC, two patient members shall be appointed for a term of three years. The other patient member and/or the patient alternate shall be appointed for a term of two years. Thereafter all appointments of the patient members shall be for a term of three years.

All other pERC members’ terms shall be for a term of two or three years.

The term of any pERC member, including a patient member, may be renewed at the discretion of the President and CEO of CADTH. Generally, pERC members will be limited to serving two consecutive terms, unless otherwise decided by the President and CEO of CADTH.

Notwithstanding anything set out in these terms of reference, the President and CEO of CADTH shall have the right to remove and/or replace a pERC member at or before the expiry of his/her term.

5.6 Withdrawal from Committee
An individual may resign as a pERC member at any time upon written notification to both the pCODR Director and the pERC Chair.
pERC members who are absent for more than three pERC meetings per year will automatically forfeit membership on the pERC. However, the pERC Chair has the discretion to approve, in advance, an extended absence of any pERC member.

5.7 Voting Rights
Each pERC member, including the pERC Chair and each patient member, shall be entitled to one vote on all matters coming before the pERC. However, in case of an equality of votes, the motion put forward would fail and a new motion would need to be proposed.

6 Committee Support
Secretariat and administrative support for the pERC is provided by pCODR staff.

7 Meetings
7.1 Frequency of Meetings
The pERC will meet in-person on a monthly basis on a pre-specified day of each month. Under exceptional circumstances, additional meetings may be called.

7.2 Notice of Meetings
Most meetings of the pERC shall be held in Toronto, Ontario, Canada. From time to time, meetings may be held at such locations and times as either the pCODR program or the pERC Chair may determine. If a meeting must be cancelled, notice of a meeting cancellation will be provided at least two weeks in advance of a scheduled meeting date.

7.3 Quorum
The quorum at pERC meetings shall be 50 percent + 1 of the voting membership.

7.4 Attendance
pERC members shall attend all pERC meetings. A pERC member who is unable to attend an in-person meeting may request permission from the Chair to participate in the meeting via such means as video conference, teleconference or other communications facilities. The Chair shall have sole discretion in deciding whether to grant permission to such member's request but shall only grant permission in exceptional circumstances.

7.5 Attendees
In addition to pERC members, only the following persons shall be entitled to attend pERC meetings:

- a) PAC members and PAG members appointed by provincial/territorial Ministries of Health, provincial cancer agencies and federal drug programs participating in the pCODR.
- b) Clinical and Economic Guidance Panel Members and experts by invitation only (see below)
- c) pCODR staff (see below)

PAC members and PAG members appointed by provincial/territorial Ministries of Health and provincial cancer agencies participating in the pCODR shall attend as observers. At each meeting, PAG will be given the opportunity to provide its perspective on the Submission for consideration by the pERC, through the PAG Chair and/or a designated member of the PAG. PAG members shall not have the right to participate in the pERC deliberations or to vote (i.e., beyond the steps of information gathering and clarification).
Clinical and Economic Guidance Panel members and/or experts may attend the pERC meetings, by invitation of the pERC Chair only, in circumstances where the pERC has questions or requires clarifications regarding a Submission, a Resubmission, a Reconsideration of an Initial Recommendation, a Request for Advice or a pCODR guidance report. Panel members and experts, however, shall not participate in, or be present during, any pERC deliberations or vote.

The pCODR staff attending the meeting shall serve as a resource to the pERC. They provide administrative and secretariat support and may actively participate in the presentation of information, Requests for Advice, Submissions, Resubmissions and Reconsiderations of an Initial Recommendation at the request of the pERC Chair. They shall also assist in obtaining additional information and/or expert advice at the pERC’s request. pCODR staff shall not have the right to vote.

Other individuals may be invited to attend as observers, at the discretion of the pERC Chair and the pCODR program, and in accordance with the CADTH Confidentiality Guidelines and the CADTH Conflict of Interest Guidelines, which are available on the CADTH website.

7.6 Agenda

The pERC’s meeting agendas shall be developed by the pERC Chair in consultation with pCODR staff.

7.7 Conflict of Interest Disclosure

At the commencement of every meeting, the Chair shall ask pERC members and invited attendees if they have any conflicts of interest to disclose. Any pERC member or invited attendee with a conflict must disclose such conflict and comply with the pCODR Conflict of Interest Guidelines. These guidelines are available on the CADTH website.

7.8 Decisions

No decision can be made unless there is a quorum.

7.8.1 Review Standards

Every Submission, Resubmission and Reconsideration of an Initial Recommendation will be reviewed by the pERC having regard to the applicable review standard established by the pCODR.

7.8.2 Recommendations

Every Initial Recommendation or Final Recommendation shall be decided by a majority of votes. Every pERC member participating in the meeting must vote (i.e., for or against) on the motion for the adoption of a recommendation; a member cannot abstain from voting, unless they have been absent for a majority of the discussion. In the event of an equality of votes, the motion put forward would fail and a new motion would need to be proposed.

Deliberations based on a Submission or a Resubmission must result in a recommendation on the submitted drug.

Deliberations in response to a Request for Advice must result in advice for the requesting jurisdictions and may or may not result in a change to a previously issued pERC Final Recommendation.

If necessary, the pERC may defer providing a recommendation or advice pending further information. This information will be provided by the pCODR program.

7.8.3 Reasons for Recommendation

The pERC shall give reasons for recommendation in support of every Initial Recommendation and every Final Recommendation, and these reasons for recommendation will be distributed in accordance with the procedure established by the pCODR.
7.8.4 Reconsideration of an Initial Recommendation
After considering feedback on an Initial Recommendation, the pERC shall make a Final Recommendation that either upholds the Initial Recommendation or makes a change to the Initial Recommendation. Feedback may be provided by the Submitter, the manufacturer (if not the Submitter), the PAG or patient advocacy groups.

In accordance with the procedure established by pCODR, in some circumstances an Initial Recommendation may proceed to a Final Recommendation without additional deliberation and reconsideration by the pERC.

7.8.5 Redeliberation on a Submission or Resubmission
In response to a request for Procedural Review and at the direction of the President and CEO of CADTH with input from PAC, pERC may deliberate on a Submission, Resubmission or Request for Advice again, and, if appropriate, change a Final pERC Recommendation.

7.9 Record of Meetings
The pCODR program shall keep permanent records of:

a) transcripts of all pERC meetings
b) a record of key decisions and actions from all pERC meetings
c) records of every Initial Recommendation and Final Recommendation made by the pERC
d) copies of all reasons for an Initial Recommendation or a Final Recommendation given by the pERC

A record of key decisions and actions from all pERC meetings shall be prepared by pCODR staff and, after their approval by the pERC members who participated, shall be sent to all pERC members and relevant pCODR staff.

A summary of the pERC deliberations for each Submission or Resubmission discussed at a pERC meeting shall be prepared by pCODR staff and subsequently reviewed by pERC members. The summary of the pERC deliberations is not a complete record of the proceedings of the pERC meeting at which the Submission or Resubmission was discussed. The summary will be posted on the CADTH website along with the Initial and Final Recommendations.

In all circumstances in which the pERC responds to a Request for Advice, the pERC advice given in reply thereto shall be given in writing (i.e., record of advice) and will be distributed in accordance with the procedure established by the pCODR. If the pERC changes a previously issued recommendation in response to a Request for Advice, the distribution of the changed recommendation will take place in accordance with the procedure established by the pCODR. A permanent record of the pERC's deliberations, including any change to the recommendation, shall be kept.

In all circumstances in which the pERC re-deliberates on a Submission in response to a Procedural Review approved by the President and CEO of CADTH, and if the pERC changes a previously issued recommendation as a result of the re-deliberation, the distribution of the changed recommendation will take place in accordance with the procedure established by the pCODR. A permanent record of the pERC's re-deliberation, including any change to the recommendation, will be kept.

7.9.1 Subcommittees
From time to time, pERC may form subcommittees and/or working groups to fulfill its mandate. Subcommittees and working groups will report back findings to the pERC for deliberation. The reimbursement of any expenses associated with the subcommittee work requires advanced approval by the pCODR Director.
8 Reimbursement of Expenses
A reasonable remuneration or honoraria for pERC members shall be provided by CADTH.
pERC members shall be entitled to be paid reasonable expenses incurred by them in the performance of their duties.
Expenses associated with meetings (teleconference calls, web meetings, etc) will be reimbursed by CADTH.
Travel expenses will be reimbursed for in-person meetings of pERC, in accordance with CADTH’s Travel Policy.
CADTH offers a centralized travel service for all domestic travel related functions in place of using an external travel agent. Travel arrangements can be made via e-mail: travelcentral@cadth.ca.
The reimbursement of any additional expenses will require approval in advance from the Director of pCODR.

9 General Provisions
9.1 Code of Conduct
pERC members must abide by the CADTH Code of Conduct.

9.2 Conflict of Interest Guidelines
In addition to the provisions provided in Section 7.7, Conflict of Interest at pERC meetings, all pERC Members must undertake in writing to abide by the terms of the CADTH Conflict of Interest Guidelines.

9.3 Indemnification
pERC Members shall be indemnified by CADTH against personal civil liability incurred by reason of any act or omission within the scope of the members’ activity.

10 Confidentiality
It is the responsibility of pERC members to know what information is confidential and to obtain clarification from the pCODR program when in doubt. Except as compelled by applicable legal process, a pERC member must, both while having and after ceasing to have that status, treat as confidential all information regarding the policies, internal operations, systems, business or affairs of the committee and of CADTH obtained by reason of his or her status as a committee and not generally available to the public. A pERC member shall not use information obtained as a result of his or her involvement on the committee for personal benefit. Each pERC member shall avoid activities which may create appearances that he or she has benefited from confidential information received during the course of his or her duties as a committee member.

More details on confidentiality are set out in the Code of Communication and the Code of Conduct, which are available on the CADTH website.

11 Terms of Reference
The Terms of Reference for the pERC will be reviewed every 2 years or as required.
Appendix A: pCODR Guiding Principles

The pan-Canadian Oncology Drug Review evolved from the interim Joint Oncology Drug Review (iJODR), which demonstrated the value that a national collaborative platform can provide to cancer care decision-making. The objective of both iJODR and pCODR is to build the foundation for a streamlined, national cancer drug review process that supports evidence-based decision-making. Ultimately, this will improve access to a more consistent standard of care across Canada, and bring clarity for patients, health professionals and industry about how, when and why drug funding decisions are made.

The guiding principles for pCODR arose from iJODR's foundational work. They have been developed in consultation with key stakeholders, most notably the patient advocacy community.

**Governance**

A review process with governance structures which are fair, objective, transparent and accountable to patients, payers and the public.

**Health System Focus**

Cancer treatment drugs are evaluated within a review process and decision making framework that are consistent with those used for drugs for other diseases.

**Representation**

A review process that is multidisciplinary, cross-jurisdictional and collaborative in nature with appropriate input from key stakeholders and linked to other key national initiatives.

**Excellence**

A review process that reflects an ongoing commitment to excellence through incorporation of best practices in a spirit of continuous quality improvement.

**Evidence-based**

A review process with capacity for rigorous and consistent evidence-based clinical and pharmacoeconomic reviews to support evidence-based decision-making.

**Ethical Framework**

A review process that includes an ethical framework.

**Efficient and Effective**

A review process that is cost-efficient, effective and streamlined (i.e. reduced duplication) to support timely decision-making.

**Evaluation**

A review process with capacity for data capture and ongoing evaluation (decision monitoring/ performance measurement) to support continuous process improvements. In addition, capacity for health outcomes and economic impact analysis to support decision-making and planning.
Appendix B: pERC Deliberative Framework

The pan-Canadian Oncology Drug Review (pCODR) was established by the provincial and territorial Ministries of Health to assess the clinical evidence and cost effectiveness of cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions. A key aspect of this process is the work done by the pCODR Expert Review Committee (pERC). Committee members examine the clinical and economic information provided by the guidance panels, as well as patient advocacy group input and Provincial Advisory Group (PAG) input, to formulate a recommendation.

To help guide the pERC’s deliberations, the committee must follow a framework, (see Tables B1 and B2) which provides an outline of all the elements that should be considered by pERC during its review, and reinforces that no single element over-rides another, but rather that pERC uses the sum of all elements to formulate a funding recommendation. The framework can be applied to all oncology drugs and situations including situations such as rare cancers or end of life care. In addition, the framework reinforces that there is no threshold that must be met for any single element in the review; rather, it is the individual drug, disease and context that determine pERC’s information needs for each element of the framework.
<table>
<thead>
<tr>
<th>Criteria</th>
<th>Definition</th>
<th>Sub-Criteria</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Clinical Benefit</td>
<td>A measure of the net health benefit of using the drug to diagnose or manage a cancer related condition (e.g., lung cancer) or cancer care related issue (e.g., skeletal related events in metastatic disease)</td>
<td>• Effectiveness • Safety • Burden of Illness • Need</td>
<td>Clinical Guidance Report provided by Clinical Guidance Panel, which incorporates the pCODR systematic review</td>
</tr>
<tr>
<td>Alignment with Patient Values</td>
<td>An assessment made after considering information on patient values</td>
<td>• Patient values</td>
<td>Patient advocacy group input sought at beginning of the review</td>
</tr>
<tr>
<td>Cost Effectiveness</td>
<td>A measure of the net efficiency of the drug and companion technology compared to other drug and non-drug alternatives (no cut-off threshold)</td>
<td>• Economic evaluation • Costs, cost per QALY, cost per life year gained, cost per clinical event avoided • Uncertainty of net economic benefits</td>
<td>Economic Guidance Report, which incorporates the Economic Guidance Panel review of the pharmacoeconomic model.</td>
</tr>
<tr>
<td>Feasibility of Adoption into the Health System</td>
<td>An assessment of the ease with which the drug can be adopted into the overall health care and cancer care systems</td>
<td>• Economic Feasibility – Budget Impact Assessment • Organizational Feasibility</td>
<td>Provincial Advisory Group input Economic Guidance Report, which incorporates evaluation of budget impact assessment assumptions</td>
</tr>
</tbody>
</table>
Table B2: Detailed Description of Each Element of the pERC Deliberative Framework.

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Sub-Criteria</th>
<th>Sub-Criteria Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Clinical Benefit</td>
<td>Effectiveness (systematic review in the Clinical Guidance Report)</td>
<td>The potential health impact of the drug compared to the other drug and non-drug alternatives, measured in terms of relevant patient outcomes such as mortality, morbidity, quality of life. Magnitude, direction and uncertainty of effect should be considered.</td>
</tr>
<tr>
<td></td>
<td>Safety (systematic review in the Clinical Guidance Report)</td>
<td>Frequency and severity of adverse effects associated with the new drug compared to other drug and non-drug alternatives.</td>
</tr>
<tr>
<td></td>
<td>Burden of Illness (Clinical Guidance Report, patient advocacy group input)</td>
<td>Incidence, prevalence or other measure of disease burden on the population.</td>
</tr>
<tr>
<td></td>
<td>Need (Clinical Guidance Report, patient advocacy group input)</td>
<td>Availability of an effective alternative to the drug technology.</td>
</tr>
<tr>
<td>Alignment with Patient Values</td>
<td>Patient Values (patient advocacy group input)</td>
<td>Patient based values which bear on the appropriate use and impact of the drug.</td>
</tr>
<tr>
<td>Cost effectiveness</td>
<td>Economic Evaluations (Economic Guidance Report and pharmaco- economic model review)</td>
<td>A measure of the net cost or efficiency of the drug and companion technology compared to other drug and non-drug alternatives. The uncertainty of results should be considered.</td>
</tr>
<tr>
<td></td>
<td>Organizational Feasibility (Provincial Advisory Group input)</td>
<td>The ease with which the new drug can be adopted, with an assessment of health system enablers and barriers to implementation, inclusive of all elements: operational, capital, human resources, legislative and regulatory requirements.</td>
</tr>
</tbody>
</table>
Appendix C: Responsibilities of pERC Chair & pERC Vice-Chair

pERC Chair Role & Responsibilities

The pERC Chair provides leadership to the committee, represents the pERC to the President and CEO of CADTH and pCODR program and acts as the sole spokesperson of the pERC.

Specifically, the Chair:

- Presides over all pERC meetings to ensure all members fully commit to fulfilling their responsibilities as outlined under pERC Terms of Reference and its appendices.
- Reports on committee activities to the President and CEO of CADTH in an open, positive and timely manner.
  - Will assist the President and CEO of CADTH and the pCODR Director in their evaluation of the Vice-Chair position on the pCODR Expert Review Committee after one year’s time, to determine the requirement for the level of commitment outlined in the Vice-Chair’s Roles and Responsibilities
- As the main liaison between the pERC and the pCODR program, maintains constructive and collaborative relationships to maximize the impact of the committee’s work.
- Maintains the integrity of the committee and its work, by ensuring members follow the pERC Code of Conduct and Conflict of Interest Guidelines, in consultation with the pCODR program.
- Works with the pCODR program to develop the monthly pERC meeting agenda. The Vice-Chair will also assist with the development of the agenda.
- Works with the pCODR program to assign submissions to a tiered queue for review and placement on the pERC agenda. Consultation with the Provincial Advisory Group (PAG) will be sought as required.
- Considers requests from submitters for a priority review, as part of three-person panels, which could include the Vice-Chair and one additional pERC member.
- Works with the pERC Vice-Chair and pCODR Director to recruit Clinical and Economic Guidance Panel members with pan-Canadian representation, as required.
- Assists pCODR program in determining if additional expertise is required on a particular drug Review Team.
- Invites members of the Review Team, including Clinical Guidance Panel members or Economic Guidance Panel members and/or External Experts to provide in-person input at a pERC meeting, to assist in the committee’s information gathering and clarification activities.
- During pERC deliberations, determines if committee deliberations should be deferred until additional, impactful information is sought out, from the Review Team, the Submitter, or from External Experts.
- Works with the pCODR program to review feedback provided by stakeholders on an initial recommendation. Feedback will be screened by the pCODR program, in consultation with the Chair.
- Works with the pCODR program and either Economic Guidance Panel members or Clinical Guidance Panel members to assess proposed new information when screening a resubmission.
- Responsibilities under procedural review to be added once finalized by PAC.

The above role and responsibilities will be re-evaluated by the President and CEO of CADTH and pCODR Director from time to time, as required.

Remuneration

- The Chair will receive a stipend in the range of $6,000 per month.
- Any reasonable travel costs for pERC or other pCODR meetings, in accordance with CADTH’s Travel Policy.
Time commitment

- Up to 4 days per month. The Chair will be required to travel for up to once-monthly pERC meetings, which are expected to last a half day in duration.
- Once monthly pERC meetings are held in Toronto, Ontario.
- Additional travel may be requested for public/stakeholder meetings, which are generally held in Toronto, Ontario, but may be held in other cities across Canada, as required.

Term of appointment

- The appointment will be for a period of 2-3 years.
- The appointment can be renewable at the end of the appointment period, subject to satisfactory evaluation. There should be no expectation of automatic reappointment.

pERC Vice-Chair Role & Responsibilities

The pERC Vice-Chair provides assistance to the pERC Chair in carrying out the following duties:

- Is responsible for chairing meetings in the event that the pERC Chair is unable to attend a meeting. This will include any pre-meeting planning and preparatory work that would accompany chairing a specific meeting.
- Will assume the chairing of a meeting for a specific agenda item in the event that the Chair should declare a conflict of interest with regard to that specific item.
- Assists the pERC Chair with development of the monthly pERC meeting agenda.
- Facilitates the quality and efficient running of monthly pERC meetings, by assisting the pERC Chair and pCODR program in the following activities:
  - Over a 2-3 meeting period, presenting one submission or resubmission, to ensure appropriate standards are set and modeled for other pERC members.
  - Detailed review of draft recommendations prior to public posting.
  - Providing advice on policy and procedures to enhance quality of committee work.
- Assists with the recruitment of clinical and economic guidance panels with pan-Canadian representation.

Remuneration

- pERC Vice-Chair will receive $1000 per day, which is pro-rated on a hourly basis, using 7.25 hours/day.
- Any reasonable travel costs for pERC or other pCODR meetings, in accordance with CADTH’s Travel Policy.

Time commitment

- Up to 3 days per month (2 days as with all pERC member responsibilities, which includes pERC meeting time and preparation for meeting, and one additional day for pERC Vice-Chair responsibilities). pERC members will be required to travel for up to once-monthly pERC meetings, which are expected to last a half day in duration.
- Once monthly pERC meetings are held in Toronto, Ontario.
- If additional time commitment is considered, this will be negotiated between the pERC Chair and the pCODR Director in advance of the activity.
Term of appointment

- The appointment will be for a period of two to three years, to be aligned with the appointment term for the pERC Chair.
- After one year, the President and CEO of CADTH, in consultation with the pERC Chair and pCODR Director, will evaluate the roles and responsibilities for a Vice-Chair position on the pCODR Expert Review Committee, to determine the requirement for the level of commitment outlined above.
- The appointment may be renewed at the end of the term of the appointment period, subject to satisfactory evaluation. There should be no expectation of automatic reappointment.
- The successful candidate will be required to subscribe to the CADTH Code of Conduct.
- All pERC members should note the requirement to declare any potential conflict of interest that might arise in the course of pCODR business.